Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits

被引:45
作者
Groll, AH
Gullick, BM
Petraitiene, R
Petraitis, V
Candelario, M
Piscitelli, SC
Walsh, TJ
机构
[1] NCI, Immunocompromised Host Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA
[2] NIH, Warren Grant Magnuson Clin Ctr, Dept Pharm, Pharmacokinet Res Lab, Bethesda, MD 20892 USA
关键词
D O I
10.1128/AAC.45.2.596-600.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The pharmacokinetics of the antifungal echinocandin-lipopeptide caspofungin (MK-0991) in plasma were studied in groups of three healthy rabbits after single and multiple daily intravenous administration of doses of 1, 3, and 6 mg/kg of body weight. Concentrations were measured by a validated high-performance liquid chromatography method and fitted into a three-compartment open pharmacokinetic model. Across the investigated dosage range, caspofungin displayed dose-independent pharmacokinetics. Following administration over 7 days, the mean peak concentration in plasma (C-max) +/- standard error of the mean increased from 16.01 +/- 0.61 mug/ml at the 1-mg/kg dose to 105.52 +/- 8.92 mug/ml at the 6-mg/kg dose; the mean area under the curve from 0 h to infinity rose from 13.15 +/- 2.37 to 158.43 +/- 15.58 mug . h/ml, respectively, The mean apparent volume of distribution at steady state (Vd(ss)) was 0.299 +/- 0.011 liter/kg at the 1-mg/kg dose and 0.351 +/- 0.016 liter/kg at the 6-mg/kg dose (not significant [NS]). Clearance (CL) ranged from 0.086 +/- 0.017 liter/kg/h at the 1-mg/kg dose to 0.043 +/- 0.004 liter/kg/h at the 6-mg/kg dose (NS), and the mean terminal half-life was between 30 and 34 h (NS), Except for a trend towards an increased Vd(ss), there were no significant differences in pharmacokinetic parameters in comparison to those after single-dose administration, Caspofungin was well tolerated, displayed linear pharmacokinetics that fit into a three-compartment pharmacokinetic model, and achieved sustained concentrations in plasma that were multiple times in excess of reported MICs for susceptible opportunistic fungi.
引用
收藏
页码:596 / 600
页数:5
相关论文
共 23 条
  • [1] Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
    Abruzzo, GK
    Flattery, AM
    Gill, CJ
    Kong, L
    Smith, JG
    Pikounis, VB
    Balkovec, JM
    Bouffard, AF
    Dropinski, JF
    Rosen, H
    Kropp, H
    Bartizal, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2333 - 2338
  • [2] IN-VITRO EVALUATION OF THE PNEUMOCANDIN ANTIFUNGAL AGENT L-733560, A NEW WATER-SOLUBLE HYBRID OF L-705589 AND L-731373
    BARTIZAL, K
    SCOTT, T
    ABRUZZO, GK
    GILL, CJ
    PACHOLOK, C
    LYNCH, L
    KROPP, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) : 1070 - 1076
  • [3] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
    Bartizal, K
    Gill, CJ
    Abruzzo, GK
    Flattery, AM
    Kong, L
    Scott, PM
    Smith, JG
    Leighton, CE
    Bouffard, A
    Dropinski, JF
    Balkovec, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2326 - 2332
  • [4] *COMM CAR US LAB A, 1996, GUID CAR US LAB AN
  • [5] DARGENIO DZ, 1990, ADAPT 2 USERS GUIDE
  • [6] In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
    DelPoeta, M
    Schell, WA
    Perfect, JR
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) : 1835 - 1836
  • [7] In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
    Ernst, EJ
    Klepser, ME
    Ernst, ME
    Messer, SA
    Pfaller, MA
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 33 (02) : 75 - 80
  • [8] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
    Espinel-Ingroff, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) : 2950 - 2956
  • [9] Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
    Franzot, SP
    Casadevall, A
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) : 331 - 336
  • [10] Treatment of murine disseminated candidiasis with L-743,872
    Graybill, JR
    Najvar, LK
    Luther, MF
    Fothergill, AW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) : 1775 - 1777